FIELD: immunology, biology.
SUBSTANCE: invention relates to variants of IL-1β-binding molecule having common functionally active sites (CDR sites) and may bind human IL-1β. Said molecules have neutralizing activity IC50 of approximately 50 pM and binding constant KD of approximately 30 pM. Amino acid sequence is described in description of present invention. Variants of DNA constructs encoding of heavy chain and light chain of IL-1β-binding molecule are disclosed. Expression vectors carrying at least one abovementioned nuclear acid and method for production of IL-1β-binding molecules by using the same also are described.
EFFECT: IL-1β-binding molecules against human IL-1β with high neutralizing activity and binding constant useful in suppression of HAMA response.
10 cl, 1 dwg, 3 tbl, 4 ex
Title | Year | Author | Number |
---|---|---|---|
NOVEL APPLICATION OF IL-1β COMPOUNDS | 2012 |
|
RU2571563C2 |
RECOMBINED ANTIBODY TO HUMAN INTERLEUKIN 1β | 2001 |
|
RU2264413C2 |
NEW INDICATIONS FOR USE IN TREATING ANTIBODIES AGAINST IL-1-BETA | 2014 |
|
RU2698208C2 |
NEW APPLICATION OF IL-1β COMPOUNDS | 2006 |
|
RU2468817C2 |
ANTIBODIES RAISED TO HUMAN MCP-1 | 2001 |
|
RU2314316C2 |
METHOD FOR OBTAINING BI-SPECIFIC ANTIBODIES, BI-SPECIFIC ANTIBODIES AND THERAPEUTIC APPLICATION OF SUCH ANTIBODIES | 2018 |
|
RU2795240C2 |
IL-17 ANTAGONIST ANTIBODIES | 2005 |
|
RU2426741C2 |
THERAPEUTIC BINDING MOLECULES | 2002 |
|
RU2328506C2 |
ADVANCED ANTIBODY MOLECULES | 2009 |
|
RU2430111C1 |
ANTI-Nogo ANTIBODIES ("11C7") AND THEIR APPLICATION IN PHARMACEUTICS | 2003 |
|
RU2350623C2 |
Authors
Dates
2006-10-27—Published
2001-08-20—Filed